Novel identification of zyxin upregulations in the motile phenotype of hepatocellular carcinoma
Shirley M.-H. Sy(Chinese University of Hong Kong), Nathalie Wong(Chinese University of Hong Kong), Philip J. Johnson(Prince of Wales Hospital), Navy L-Y Wong(Chinese University of Hong Kong), E Pang(Chinese University of Hong Kong), Ka‐Fai To(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong)
Cited by 40
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial
|The Lancet|2004|895
Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments
|Proceedings of the National Academy of Sciences|2015|818